Status:
COMPLETED
Effect of Midazolam as Premedication in Patients Undergoing Breast Conservation Study
Lead Sponsor:
Shaukat Khanum Memorial Cancer Hospital & Research Centre
Conditions:
Anxiety
Eligibility:
FEMALE
Up to 60 years
Brief Summary
Patient are randomized into 2 groups under computer registered numbers. Patient anxiety score is calculated through APAIS SCORE. Then one group is given Midazolam, and the other group is given normal ...
Detailed Description
Patient are randomized into 2 groups under computer registered numbers. After taking approval from hospital ethical committee, 124 females fulfilling inclusion criteria are selected. All patients will...
Eligibility Criteria
Inclusion
- All patients undergoing breast conservation surgery
- ASA I-II
Exclusion
- Patients already on anxiolytic medication
- Pregnancy
- Allergy to Midazolam,
- Patient with diagnosed psychosis,
- Chronic kidney disease.
Key Trial Info
Start Date :
August 30 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 10 2025
Estimated Enrollment :
124 Patients enrolled
Trial Details
Trial ID
NCT07184125
Start Date
August 30 2024
End Date
September 10 2025
Last Update
January 8 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shaukat Khanam Cancer Memorial Hospital Lahore
Lahore, Punjab Province, Pakistan, 54000